Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 3OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 5Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1GATA2 Deficiency 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 13fludarabine phosphate 10Peripheral Blood Stem Cell Transplantation 8Etoposide 7Busulfan 7Methotrexate 6Cyclophosphamide 6Azacitidine 6Vorinostat 5Idarubicin 5Filgrastim 5Decitabine 5Daunorubicin 5tipifarnib 4Topotecan 4Carboplatin 4Biopsy 4veliparib 3sargramostim 3laromustine 3entinostat 3Thioguanine 3Tacrolimus 3Sunitinib 3Lenalidomide 3Imatinib Mesylate 3Cyclosporine 3Antilymphocyte Serum 3romidepsin 2merphos 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Myelomonocytic, Chronic × decitabine and cedazuridine drug combination × Clear all
NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡